Global PD-1 And PDL-1 Inhibitor Market Worth USD 106.49 Billion By 2031 | CAGR of 14.87%

Introduction

Inhibitors of PD-1 and PDL-1 are immunotherapeutic drugs used to treat a variety of cancer indications, primarily in advanced stages. PD-1/PDL-1 inhibitors are primarily IgG1 and IgG4 monoclonal antibodies injected into patients. The current market for PD-1 and PDL-1 inhibitors has seven commercially accessible, FDA-approved medicines. Four of the commercially available medications inhibit PD-1, whereas three inhibit PDL-1.

Market Dynamics

Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications Drives the Global Market

The immune system is essential for the development and progression of cancer. The immune system of the host aids in identifying and destroying cancer cells. These immune checkpoint inhibitors prevent cancer cells from evading resistant identification. Immune checkpoint inhibitors are being studied for their therapeutic potential in various cancer indications due to their advantages over conventional cytotoxic therapies. The rising use of immune checkpoint inhibitors across multiple cancer indications has broadened its product offering. Since its debut in 2014, Merck Sharp & Dohme Corporation gained over thirty indications for its PD-1 Inhibitor Keytruda (Pembrolizumab). Opdivo (Nivolumab), another PD-1 inhibitor from Bristol-Myers Squibb, has been approved for more than 25 indications.

Promising Therapeutic Outcomes Creates Tremendous Opportunities

All patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer exhibited complete clinical responses following six months of neoadjuvant therapy with Dostarilumab. This extraordinary therapeutic outcome, combined with better overall survival in other cancer patients receiving PD-1/PDL-1 inhibitors, is anticipated to increase prescribers' and patients' confidence. The reported excellent therapeutic outcomes and the evaluation of the role of PD-1/PDL-1 inhibitors in a rising variety of cancer indications and particular subsets offer substantial prospects for PD-1/PDL-1 inhibitor therapy.

Regional Analysis

North America is the most significant shareholder in the global PD-1 and PDL-1 inhibitor market and is expected to grow significantly over the forecast period. The increased incidence of cancer in the United States, especially lung cancer, urothelial carcinomas, and skin cancer, has led to this dominance. Factors driving the growth of the US PD-1 and PD-L1 inhibitors are key product launches, high concentrations of market participants or manufacturers' presence, acquisitions and partnerships among significant players, and critical product launches by PD-1 and PD-L1 inhibitors companies in the country. According to Novartis, the FDA approved the Biologics License Application (BLA) for the anti-PD-1 immune checkpoint inhibitor tislelizumab in September 2021 to treat patients with recurrent, unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior systemic therapy.

Germany is expected to enjoy highly rapid growth compared to other European nations due to the numerous clinical trials being undertaken in the industry. Organizations such as the European Medicines Agency have emphasized PD-1/PD-L1 inhibitors for combination therapy and monotherapy trials for young patients to treat diseases in adults. The market's growth in Germany can also be attributed to increased knowledge of PD-1/PD-L1 inhibitors' low toxicity levels and compliance with local healthcare safety regulations.

Key Highlights

• The global PD-1 and PDL-1 inhibitor market was valued at USD 30,524.47 million in 2022. It is estimated to reach USD 106,495 million by 2031, growing at a CAGR of 14.87% during the forecast period (2023–2031).
• By inhibitors type, the global PD-1 and PDL-1 inhibitor market is segmented into the PD-1 inhibitor and PDL-1 inhibitor. The PD-1 inhibitor is the highest contributor to the market and is expected to grow significantly during the forecast period.
• By indications, the global PD-1 and PDL-1 inhibitor market is divided into non-small cell lung cancer (NSCLC), melanoma, hepatocellular carcinoma (HCC), colorectal cancer (CRC), breast cancer, and urothelial carcinoma. The non-small cell lung cancer (NSCLC) segment owns the highest market share and is expected to grow significantly during the forecast period.
• By the development phase, the global PD-1 and PDL-1 inhibitor market is divided into phase I, phase II, phase III, and phase IV. The phase I segment is the highest contributor to the market and is expected to grow significantly during the forecast period.
• North America is the most significant shareholder in the global PD-1 and PDL-1 inhibitor market and is expected to grow significantly over the forecast period.

Competitive Players

Competitive Players

The key players in the global PD-1 and PDL-1 inhibitor market are Arcus Biosciences, Inc., Amgen Inc., AstraZeneca Plc, Biocad, BeiGene Ltd., Bristol Myers Squibb Co., Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Incyte Corporation, Lee's Pharmaceutical Limited, and CStone Pharmaceuticals and Shanghai Jhunsi Biosciences Ltd.

Recent Developments

Market News

• In December 2022, Hoffman La Roche Ltd. announced that Lunsumio® (mosunetuzumab-axgb) had been approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed/refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
• In December 2022, Hoffman La Roche Ltd announced that it entered into a U.S.-focused collaboration with Pfizer to raise awareness and educate about the significance of timely COVID-19 testing, available treatment options, symptoms, and high-risk variables that can increase the likelihood of developing severe illness.

Segmentation

Global PD-1 and PDL-1 Inhibitor Market: Segmentation

By Inhibitors Type

• PD-1 Inhibitors
• PD-L1 Inhibitors

By Indications

• Non-Small Cell Lung Cancer (NSCLC)
• Melanoma
• Hepatocellular Carcinoma (HCC)
• Colorectal Cancer (CRC)
• Breast Cancer
• Urothelial Carcinoma

By Development Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa